J 2021

Second primary malignancies in colorectal cancer patients

HALÁMKOVÁ, Jana, Tomáš KAZDA, Lucie PEHALOVÁ, Roman GONĚC, Šárka KOZÁKOVÁ et. al.

Basic information

Original name

Second primary malignancies in colorectal cancer patients

Authors

HALÁMKOVÁ, Jana (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, guarantor, belonging to the institution), Lucie PEHALOVÁ (203 Czech Republic, belonging to the institution), Roman GONĚC (203 Czech Republic, belonging to the institution), Šárka KOZÁKOVÁ (203 Czech Republic), Lucia BOHOVICOVÁ (203 Czech Republic), Dagmar KRAKOROVA ADAMKOVA (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution) and Igor KISS (203 Czech Republic, belonging to the institution)

Edition

Nature Scientific Reports, London, NATURE RESEARCH, 2021, 2045-2322

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.996

RIV identification code

RIV/00216224:14110/21:00121474

Organization unit

Faculty of Medicine

UT WoS

000617705600001

Keywords in English

colorectal cancer; second primary malignancies

Tags

International impact, Reviewed
Změněno: 28/2/2022 10:08, Mgr. Tereza Miškechová

Abstract

V originále

The prevalence of second primary malignancies (SPMs) in the western world is continually increasing with the risk of a new primary cancer in patients with previously diagnosed carcinoma at about 20%. The aim of this retrospective analysis is to identify SPMs in colorectal cancer patients in a single-institution cohort, describe the most frequent SPMs in colorectal cancer patients, and discover the time period to occurrence of second primary tumors. We identified 1174 patients diagnosed with colorectal cancer in the period 2003-2013, with follow-up till 31.12.2018, and median follow-up of 10.1 years, (median age 63 years, 724 men). A second primary neoplasm was diagnosed in 234 patients (19.9%). Older age patients, those with early-stage disease and those with no relapse have a higher risk of secondary cancer development. The median time from cancer diagnosis to development of CRC was 8.9 years for breast cancer and 3.4 years for prostate cancer. For the most common cancer diagnosis after primary CRC, the median time to development was 0-5.2 years, depending on the type of malignancy. Patients with a diagnosis of breast, prostate, or kidney cancer, or melanoma should be regularly screened for CRC. CRC patients should also be screened for additional CRC as well as cancers of the breast, prostate, kidney, and bladder. The screening of cancer patients for the most frequent malignancies along with systematic patient education in this field should be the standard of surveillance for colorectal cancer patients.

Links

90125, large research infrastructures
Name: BBMRI-CZ III
90128, large research infrastructures
Name: CZECRIN III